Case Study: Brickell Biotech achieves streamlined, paperless equity management from private to public with Carta

Brickell Biotech manages their equity from private to public on Carta

Brickell Biotech, a clinical-stage pharmaceutical company focused on skin-disease therapeutics, struggled to manage frequent equity grants and cap table updates manually using Excel and paper-based processes. To scale administration and make equity management easier for administrators and shareholders, Brickell Biotech adopted Carta’s equity management platform and services.

Carta centralized Brickell Biotech’s cap table, digitalized documents and communications, and took over 409A valuations—eliminating the need for a separate consulting firm and enabling multiple valuations per year. The result for Brickell Biotech was significant time savings for administrators, no more paper or mailed documents, happier shareholders, and a smooth transition to managing equity as a public company on Carta.

Brickell Biotech

Jose Breton

Chief Accounting Officer